Hematologic Malignancy
Small Lymphocytic Lymphoma
CI-CAN-00003981SLLExplore in graph →
Hematologic129 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003981SLLExplore in graph →
Clinical trials
479 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (108)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 | clinicaltrials |
| NCT03734016 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia(ALPINE) | completed | Phase 3 | 652 | BeiGeneINDUSTRY | 15 | Mar 30, 2025 |
| clinicaltrials |
| NCT01724346 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Sep 19, 2024 | clinicaltrials |
| NCT03078855 | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma(ILyAD) | completed | Phase 3 | 211 | Jonathan FriedbergOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT02004522 | A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | completed | Phase 3 | 319 | SecuraBioINDUSTRY | 11 | Sep 21, 2023 | clinicaltrials |
| NCT02049515 | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 | completed | Phase 3 | 99 | SecuraBioINDUSTRY | 11 | Sep 21, 2023 | clinicaltrials |
| NCT01611090 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 578 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 3, 2020 | clinicaltrials |
| NCT01578707 | A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(RESONATE™) | completed | Phase 3 | 391 | Pharmacyclics LLC.INDUSTRY | 10 | Dec 18, 2019 | clinicaltrials |
| NCT01973387 | A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma | completed | Phase 3 | 160 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 24, 2018 | clinicaltrials |
| NCT01722487 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Nov 30, 2017 | clinicaltrials |
| NCT00801281 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.(PLRG4) | completed | Phase 3 | 250 | Polish Lymphoma Research GroupNETWORK | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00003204 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma | completed | Phase 3 | 515 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Apr 30, 2026source: clinicaltrials